What visual side effects are associated with high‑dose ivermectin (≥600–800 µg/kg) and how do they resolve?

Visual Side Effects of High-Dose Ivermectin

High-dose ivermectin (≥600–800 µg/kg) causes transient visual disturbances including blurred vision, perception of red dots in peripheral vision, and subjective ocular complaints that typically resolve completely within 10–24 hours without permanent sequelae.

Specific Visual Manifestations

The visual side effects associated with high-dose ivermectin include:

• Blurred vision is the most commonly reported visual complaint, occurring significantly more frequently with doses ≥800 µg/kg compared to standard dosing 1, 2
• Perception of red dots or visual hallucinations in the peripheral visual field has been documented in pediatric cases receiving supratherapeutic doses (1 mg/kg or 10 times the recommended dose) 3
• Complex visual hallucinations can occur when ivermectin is combined with other metabolic stressors, though this appears related to overall toxicity rather than isolated ocular effects 4
• Pulsating pupils (mydriasis with rhythmic changes) have been observed on physical examination in acute toxicity cases 3
• Transient blurred vision occurred in 5.6% of patients receiving 400–600 µg/kg daily for 3 days in a controlled trial, compared to only 0.6% in placebo (p < 0.001) 2

Dose-Response Relationship

The frequency and severity of visual complaints are clearly dose-dependent:

• Standard doses (150–200 µg/kg) carry minimal risk of visual side effects 1
• High doses (800 µg/kg) show significantly increased frequency of transitory subjective visual problems compared to standard dosing 1
• Supratherapeutic doses (≥1 mg/kg) reliably produce acute visual disturbances within 10 hours of ingestion 3

A randomized controlled trial in Cameroon demonstrated that groups receiving 800 µg/kg ivermectin reported significantly more transitory ocular complaints than the reference group receiving 150 µg/kg, though ophthalmological examination revealed only mild early iris lesions without permanent damage 1.

Mechanism and Ophthalmological Findings

The pathophysiology of these visual effects remains incompletely understood:

• Anterior chamber microfilariae reduction occurs more rapidly with high-dose regimens, but this does not fully explain the subjective visual complaints 1
• Early iris lesions were documented at higher prevalence in the high-dose annual treatment group during initial examination, though these were transient 1
• No permanent ocular damage has been documented in systematic reviews, with all ocular events classified as transient and mild to moderate in intensity 5

The disconnect between subjective visual complaints and objective ophthalmological findings suggests the mechanism may involve transient effects on neural processing or retinal function rather than structural damage 1.

Resolution Timeline

Visual side effects follow a predictable resolution pattern:

• Onset: Visual symptoms typically begin 10 hours after ingestion of high doses 3
• Peak: Symptoms are most pronounced within the first 24 hours 4, 3
• Resolution: Complete resolution occurs within 10–24 hours without intervention in most cases 4, 3
• No permanent sequelae: All documented cases show complete recovery without lasting visual impairment 4, 3, 5

Clinical Management

When high-dose ivermectin visual toxicity is suspected:

• Supportive care only is required, as symptoms are self-limiting 4, 3
• Activated charcoal may be considered if presentation is within hours of ingestion, though visual symptoms will still resolve spontaneously 4
• Reassurance is critical, as patients and families may be alarmed by acute visual changes 3
• Observation for 24 hours is sufficient to document complete resolution 4, 3
• No specific ophthalmological intervention is needed, as structural damage does not occur 1, 5

Critical Caveats for Onchocerciasis Patients

A special warning applies to patients with onchocerciasis: While visual side effects are transient in otherwise healthy individuals, patients with active onchocerciasis receiving high-dose ivermectin showed increased ocular events in clinical trials 5. This is concerning because:

• The ocular events, though transient and mild-to-moderate, occurred more frequently in the higher-dose group 5
• These data suggest high-dose ivermectin (>400 µg/kg) should be used with caution in onchocerciasis patients 1, 5
• Standard dosing (150–200 µg/kg) remains the safest approach for this population 1

Practical Implications

For clinicians encountering patients with suspected ivermectin-related visual disturbances:

• Obtain detailed dosing history, as visual effects reliably indicate supratherapeutic dosing (≥600 µg/kg) 3, 1, 2
• Consider ivermectin toxicity in any patient presenting with acute blurred vision, peripheral visual phenomena, and ataxia, especially in the context of COVID-19 self-medication 3
• Document pupillary findings, as pulsating pupils are a specific physical examination finding 3
• Expect complete resolution within 24 hours and counsel patients accordingly 4, 3
• Do not use high-dose regimens (>400 µg/kg) outside of controlled research settings, as the safety profile does not support routine clinical use 1, 5